As U.S. President Donald Trump threatens a new round of tariffs as part of an onshoring push, Chinese President Xi Jinping is ...

Billionaire Dalio, head of the world's largest hedge fund, is considered a global authority on investing in China. The bank ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Thousands of 3D protein structures locked up in big-pharma vaults will be used to create a new AI tool that won’t be open to ...

Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Automated three-dimensional total-body photography improves the efficiency of positive malignant biopsies and reduces ...

Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...

A new medical database automatically compiles the medical records of obese patients and those suffering from obesity-related diseases in a uniquely comprehensive and reliable manner. The initiative, ...

DelveInsight’s, “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline ...

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

Boehringer Ingelheim has axed development of a potential therapy for Alzheimer’s after it failed in a phase 2 trial and will focus instead on developing the drug as a treatment for schizophrenia.